IRWD (Ironwood Pharmaceuticals, Inc.) חוב לטווח קצר להון

Ironwood Pharmaceuticals (IRWD) is a recognized leader in gastrointestinal therapy, a name associated with high drug efficacy and physician trust. However, the business remains vulnerable due to its reliance on Asian contractors and logistical threats. The current metric stands at 0.00. This chart illustrating the price evolution of the quotes confirms the ecosystem's resilience, driven by patient loyalty and the approval of new FDA regulations.

Defensive assets are selected based on the criterion of minimal dependence on short-term refinancing. Ironwood Pharmaceuticals (IRWD) adheres to this principle due to stable cash flow from the sale of its patented gastrointestinal drug. The ratio of current loans to equity, reflected in the trend of short-term liabilities to capital, measures liquidity risk. A decrease in this coefficient confirms the financial stability and fundamental maturity of the company's capital structure.